Chronic Lymphocytic Leukemia

Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.

Overall, the investigators observed that the CR, undetectable minimal residual disease rates, progression free survival, and overall survival amomg the patients enrolled in the trial were favorable.

AstraZeneca trial results shows 90% of patients with chronic lymphocytic leukemia surviving for 5 years.

Lisa Nodzon, PhD, ARNP, AOCNP; Katie Tobon, PharmD, BCOP; and Javier Pinilla-Ibarz, MD, PhD, share insight on strategies for the monitoring and management of BTK inhibitor–associated toxicities in CLL and review the importance of a multidisciplinary approach to treatment.

Acalabrutinib (Calquence; AstraZeneca) provides efficacy while maintaining favorable tolerability for patients with chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, evaluate novel agents and combinations in the pipeline for the management of CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, comment on the role of pharmacists in clinical practice for managing patients with CLL.

Katie Tobon, PharmD, BCOP, leads the discussion comparing dosing and drug interactions among the FDA-approved BTK inhibitors ibrutinib and acalabrutinib for the treatment of CLL.

Key opinion leaders in hematology-oncology share recommendations on switching from first-generation BTK inhibitors to next-generation BTK inhibitors for the management of patients with CLL.

Dr Ryan Jacobs, MD, leads a review of the phase 3 SEQUOIA trial presented at ASH 2021 evaluating the use of zanubrutinib for previously untreated CLL and discusses the management of adverse events with BTK inhibitors.

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, provide insight on considerations when choosing a BTK inhibitor for initial treatment of chronic lymphocytic leukemia.

Experts in hematology/oncology discuss goals of therapy and optimal treatment selection for patients with chronic lymphocytic leukemia.

Javier Pinilla-Ibarz, MD, PhD, highlights key clinical trials in CLL assessing the safety and efficacy of FDA-approved BTK inhibitors ibrutinib and acalabrutinib.

Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.

Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.

Katie Tobon, PharmD, BCOP, and Javier Pinilla-Ibarz, MD, PhD, discuss factors to consider when selecting a BTK inhibitor for CLL therapy, including cytogenetic abnormalities as well as patient- and treatment-related factors.

Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.

Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.

Dr Javier Pinilla-Ibarz leads the discussion on the role of targeted therapy over chemoimmunotherapy as a CLL therapeutic approach and shares NCCN Guidelines recommendations for the use of BTK inhibitors.

Anthony Perissinotti, PharmD, BCOP, explains potential scenarios requiring anti-CD20 monoclonal antibodies as a therapy for chronic lymphocytic leukemia.

Kirollos Hanna, PharmD, BCPS, BCOP, reviews the use of anti-CD20 monoclonal antibodies for treating chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, provide insight on NCCN guideline recommendations for molecular testing in CLL and discuss the prevalence of testing for cytogenetic abnormalities.

Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.

A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.

Drs Katie Tobon and Javier Pinilla-Ibarz explore the role of prognostic molecular testing in chronic lymphocytic leukemia and comment on challenges seen with referral patients that come from community practices.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, review challenges in CLL therapy, including cost barriers.

Kirollos Hanna, PharmD, BCPS, BCOP, discusses clinical trial data for second-generation BTK inhibitors for chronic lymphocytic leukemia.